According to the literature, the combination of the DNA-PK inhibitor M3814 with type 2 TOPO inhibitors, including doxorubicin, etoposide, and pegylated liposomal doxorubicin, has enhanced the efficacy of type 2 TOPO inhibitors in mouse xenograft ovarian cancer models 61. This evidence concerns the gene PRKDC and ovarian cancer.